NCT07641686

Brief Summary

A total of 120 Chinese male subjects aged 18-50 years who have undergone hair transplantation are planned to be enrolled in this study. Among them, 90 participants with mild-to-moderate scalp seborrheic dermatitis (hereinafter abbreviated as SD) will be stratified and randomly allocated into two groups based on a randomization table with stratification factors including SD severity grading, alopecia classification and age. Subjects in the test product group (hereinafter referred to as the holistic group) will use the test shampoo plus basic shampoo, while those in the basic control group will receive only basic shampoo. The remaining 30 non-SD subjects will constitute the non-SD control group and use basic shampoo alone.

  1. 1.Primary Objective To compare pre- and post-treatment changes in clinical, physiological, biological and microecological parameters related to SD manifestations, scalp health and skin barrier repair (including transepidermal water loss, scalp hydration, scalp sebum content, etc.) between the holistic group receiving the investigational shampoo regimen and the basic control group via non-invasive instrumental measurement, clinical assessment, clinical photography and subject self-evaluation. The safety and efficacy of the test product in improving scalp condition and skin barrier function will be evaluated, and its potential underlying mechanisms will be explored.
  2. 2.Secondary Objective To investigate the impacts of the test product versus the control shampoo on hair transplant-associated complications (e.g., folliculitis), wound healing, follicular shedding phase, graft survival rate and hair growth parameters among SD patients.
  3. 3.Exploratory Objective To collect baseline clinical, physiological, biological and scalp microecological data from non-SD recipients after hair transplantation for reference purposes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
17mo left

Started Feb 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Feb 2025Dec 2027

Study Start

First participant enrolled

February 21, 2025

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 8, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 11, 2026

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

June 11, 2026

Status Verified

June 1, 2026

Enrollment Period

2.9 years

First QC Date

June 8, 2026

Last Update Submit

June 8, 2026

Conditions

Outcome Measures

Primary Outcomes (5)

  • Scalp Seborrheic Dermatitis Assessment

    Physicians assess scalp seborrheic dermatitis (SD) in study participants and record scores and grades.

    14 days before enrollment, the day of enrollment, and 7 days, 28 days, 3 months, 6 months, and 9 months after enrollment.

  • Alopecia Grade Assessment

    Physicians assess the alopecia grade of study participants and record the corresponding scores and grades.

    14 days before enrollment, and 28 days, 3 months, 6 months, and 9 months after enrollment.

  • Scalp sebum content measurement using Sebumeter

    The instrument operates based on the photometric principle: a special opaque tape with a thickness of 0.1 mm absorbs sebum on the human skin and becomes translucent, resulting in a change in its light transmittance. The more sebum the tape absorbs, the higher its light transmittance, allowing the skin sebum content to be measured. Two points are measured on both the donor site and the recipient site, with one measurement taken at each point.

    14 days before enrollment, the day of enrollment, 7 days, 28 days, 3 months, 6 months, and 9 months after enrollment

  • Scalp stratum corneum moisture content measurement using Dermalab

    This instrument measures stratum corneum moisture content based on the principle of electrical conductivity. Its unique probe design with eight needle-shaped electrodes allows reliable measurements even on the hairy scalp.The higher the measured value, the greater the moisture content.The technician refers to the measurement point diagram and follows the randomization table to select either the left or right side of the participant's scalp at random. The scalp moisture content is measured at the central point of the selected half-scalp (either the central area of the left half or the right half). One point is measured at the donor site and one at the recipient site, with three measurements taken at each point.

    14 days before enrollment, the day of enrollment, 7 days, 28 days, 3 months, 6 months, and 9 months after enrollment

  • Transepidermal Water Loss (TEWL) measurement using Vapometer

    The measuring probe of this instrument is a sealed cylindrical chamber. When placed in contact with the scalp, the relative humidity (RH %) inside the chamber rises, based on which the transepidermal water loss (TEWL) is calculated. A lower TEWL value indicates better skin barrier function.Referring to the position diagram and measurement randomization table, the technician performs TEWL measurement at the central point on either the left or right half of the participant's scalp. One point is tested on the donor site and one on the recipient site, with three replicates taken at each point.

    14 days before enrollment, the day of enrollment, 7 days, 28 days, 3 months, 6 months and 9 months after enrollment

Secondary Outcomes (8)

  • Subjective Symptom Assessment Questionnaire (Not required for NSD population)

    14 days before enrollment, the day of enrollment, and 7 days, 28 days, 3 months, 6 months, and 9 months after enrollment.

  • Product Usage Experience Feedback Questionnaire

    9 months after enrollment

  • Product Use Compliance Questionnaire

    the day of enrollment, and 28 days, 3 months, 6 months, and 9 months after enrollment.

  • Wound Healing Assessment

    7 days and 28 days after enrollment

  • Product Efficacy and Satisfaction Questionnaire

    the day of enrollment, and 28 days, 3 months, 6 months, and 9 months after enrollment.

  • +3 more secondary outcomes

Other Outcomes (3)

  • Evaluation of Complications and Adverse Reactions

    the day of enrollment (used for adverse reaction evaluation), as well as 7 days, 28 days, 3 months, 6 months, and 9 months after enrollment

  • Tape stripping sampling

    14 days before enrollment, the day of enrollment and 28 days after enrollment

  • Scaling scraping collection

    14 days before enrollment, the day of enrollment, 7 days, 28 days, 3 months, 6 months and 9 months after enrollment

Study Arms (3)

Test Shampoo Group (SD)

EXPERIMENTAL

SD subjects receiving test shampoo plus basic shampoo

Other: Intervention Name:Test shampoo + basic shampoo for scalp care

Basic Control Group (SD)

ACTIVE COMPARATOR

SD subjects receiving basic shampoo alone

Other: Basic scalp care shampoo

Non-SD Control Group

ACTIVE COMPARATOR

Non-SD subjects receiving basic shampoo alone

Other: Basic scalp care shampoo

Interventions

Basic shampoo is adopted consistently during three research periods: pretreatment stage (14 days before enrollment to enrollment day), first test stage (7th study day to 28th study day), and follow-up stage (28th study day to the 9th trial month). The standard usage frequency is 3 times weekly; participants with daily hair-washing habit are permitted to use basic shampoo every single day.All participants must finish shampooing at home 12-36 hours prior to each study visit and keep the same pre-visit shampooing interval all through the trial.

Basic Control Group (SD)Non-SD Control Group

The whole intervention is split into three sequential research stages: the pretreatment stage, the first test stage and the long-term follow-up stage. 1.14 days before enrollment up to the day of enrollment: Test shampoo A is used 3 times every week. If participants habitually wash hair every day, they shall use test shampoo A for 3 fixed weekly washes, and use basic shampoo for all other remaining shampooing times. 2.From the 7th study day to the 28th study day: Test shampoo B is used 3 times every week. Daily shampooing users apply test shampoo B 3 times weekly, and basic shampoo for additional hair washing. 3.From the 28th study day to the 9th month of the trial: Test shampoo A is used once weekly plus basic shampoo twice weekly. For daily shampoo users, test shampoo A can be flexibly used 1 to 3 times per week, with basic shampoo used for leftover washing times.

Test Shampoo Group (SD)

Eligibility Criteria

Age18 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy Chinese male subjects aged between 18 and 55 years old;
  • Diagnosed with androgenetic alopecia, with alopecia grade from Grade II to Grade VI per Hamilton-Norwood classification;
  • Scheduled to receive hair transplantation; scalp condition is confirmed suitable for trial participation by dermatologist assessment after hair graft surgery;
  • With or without mild-to-moderate scalp seborrheic dermatitis (SD score ranging from 0 to 9);
  • No anti-dandruff shampoo used within the latest 14 days prior to enrollment;
  • No hair dyeing, perming or hair styling cosmetic treatments in the past 30 days;
  • Able to comply with all scheduled study visits;
  • Possess normal communication and comprehension capacity;
  • Agree to regular follow-up visits and complete related questionnaires on time;
  • Fully understand trial procedures, volunteer to join the study and provide written informed consent.

You may not qualify if:

  • Suffering from severe scalp seborrheic dermatitis;
  • Received oral or topical antifungal drugs, glucocorticoids or other therapeutic medicines for seborrheic dermatitis within the preceding 30 days;
  • Complicated with other scalp diseases (such as psoriasis), or with obvious infection or unhealed wounds on the target treatment area;
  • Known hypersensitivity to ingredients including selenium disulfide, salicylic acid and related components;
  • History of autoimmune diseases or severe organic diseases involving heart, brain, lung, liver, kidney and other vital organs;
  • Past medical history of psychiatric or psychological disorders;
  • Refuse to sign the written informed consent form;
  • Currently enrolled in another interventional clinical trial;
  • Diagnosed with alopecia areata, pseudopelade, cicatricial alopecia or other scalp and hair disorders;
  • Have taken part in any other clinical trial within the prior 3 months;
  • Judged as inappropriate for trial participation based on investigator's clinical assessment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Dermatitis, Seborrheic

Condition Hierarchy (Ancestors)

DermatitisSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland DiseasesSkin Diseases, EczematousSkin Diseases, Papulosquamous

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2026

First Posted

June 11, 2026

Study Start

February 21, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

June 11, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations